This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human R-Spondin 3 / RSPO3 (22-146) Protein, His Tag
catalog :
RS6-H5222
quantity :
50 ug, 1 mg
price :
260 USD, 1800 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
RS6-H5222
product name :
Human R-Spondin 3 / RSPO3 (22-146) Protein, His Tag
quantity :
50 ug, 1 mg
price :
260 USD, 1800 USD
quantity & price :
$260/50ug,$1800/1mg
target :
R-Spondin 3
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human R-Spondin 3 (22-146), His Tag (RS6-H5222) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Val 146 (Accession # AAH22367.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human R-Spondin 3 (22-146), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
R-Spondin 3 (RSPO3) is also called cysteine-rich and single thrombospondin domain containing-1 (CRISTIN1), Protein with TSP type-1 repeat (PWTSR), is a member of the R-spondin protein family. R-spondins (RSPO) are a recently discovered secretory protein family with four members in human and mouse. Although all four RSPO proteins activate the canonical Wnt pathway, RSPO2 and RSPO3 are more potent than RSPO1, whereas RSPO4 is relatively inactive. RSPO-3 is expressed ubiquitously and expressed at higher level in placenta, small intestine, fetal thymus and lymph node. RSPO3 is the activator of the beta-catenin signaling cascade, leading to TCF-dependent gene activation. RSPO3 acts both in the canonical Wnt/beta-catenin-dependent pathway and in non-canonical Wnt signaling pathway, probably by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signaling pathway. RSPO3 also acts as a ligand for frizzled FZD8 and LRP6 and may negatively regulate the TGF-beta pathway.
References :
(1) Chen J.-Z., et al., 2002, Mol. Biol. Rep. 29:287-292.
(2) Kim KA,, et al., 2006, Cell Cycle 5 (1): 23–6.
(3) Kazanskaya O., 2004, Dev Cell 7 (4): 525–34.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments